Abstracts tagged "Administrative Data"

Abstract Number: 0713 • ACR Convergence 2022
The Epidemiology, Clinical Outcomes, and Healthcare Resource Utilization of IgG4-Related Disease Among Commercially Insured People in the United States
Zachary Wallace¹, Gandarvaka Miles², Ekaterina Smolkina³, Natalia Petruski-Ivleva², Duane Madziva², Claire Cook¹, Xiaoqing Fu¹, yuqing zhang⁴, John Stone⁵ and Hyon Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Sanofi, Unknown, ³Sanofi, Amsterdam, Netherlands, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition that causes fibroinflammatory lesions, often presenting as pancreatitis, cholangitis, sialoadenitis, and retroperitoneal fibrosis. The epidemiology of IgG4-RD,…
Abstract Number: 1978 • ACR Convergence 2022
Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
Alexandra Legge¹ and Diane Lacaille², ¹Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Frailty is increasingly recognized among individuals living with RA. While several tools are available to assess frailty in clinical settings, it is less readily…
Abstract Number: 0065 • ACR Convergence 2022
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
Tarun Sharma¹, paul lebovitz¹, chetan rajput², Lori Mcaninch³, ellen Kraemer³, izabela Stanescu³, adam dore¹, joseph ahearn³ and Susan Manzi⁴, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, ³Allegheny Health Network, Pittsburgh, ⁴Allegheny Health Network, Lupus Center of Excellence, Wexford, PA
Background/Purpose: Care transformation in a chronic illness like RA requires delivery of health care services through a patient-centric care model. Within an integrated delivery and…
Abstract Number: 0723 • ACR Convergence 2022
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Lea Hoisnard¹, Laura Pina Vegas², Rosemary Dray-Spira³, Alain Weill³, Mahmoud Zureik³ and Emilie sbidian⁴, ¹Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France, ²Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France, ⁴Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
Background/Purpose: To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib…
Abstract Number: 2057 • ACR Convergence 2022
Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
Meghan Nelson¹, Colleen Mosley², D. Sofia Villacis-Nunez³, Kelly Rouster-Stevens³ and Amit Thakral³, ¹Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children's Healthcare of Atlanta, Atlanta, GA, ²Children’s Healthcare of Atlanta, Atlanta, GA, ³Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that is associated with significant disease damage, morbidity, and mortality. In comparison to the adult…
Abstract Number: 0066 • ACR Convergence 2022
Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database
Emily Smitherman¹, Rouba Chahine¹, Aimee Hersh² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Data is lacking regarding modern real-world practices and disease outcomes of individuals with childhood-onset systemic lupus erythematosus (cSLE) and lupus nephritis, especially across multiple…
Abstract Number: 0750 • ACR Convergence 2022
Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization
Victoria Furer, Hagit Sarbagil-Maman and Ori Elkayam, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are susceptible for pneumococcal disease. Two vaccines against S. pneumoniae are currently recommended for use: a 23-valent…
Abstract Number: 2062 • ACR Convergence 2022
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
Sandra Sze-jung Wu¹, Allison Perry², Nicole Zimmerman³, Helen Varker⁴, Rich Bizier⁴, Liisa Palmer⁴, Christine Dube⁵ and Gary Bryant⁶, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³IBM Watson Health, Chagrin Falls, OH, ⁴Merative, Cambridge, MA, ⁵AstraZeneca, Torrington, CT, ⁶AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an…
Abstract Number: 0068 • ACR Convergence 2022
Differential Diagnostic Coding Patterns and Associated Sociodemographic Factors in Childhood-Onset Lupus Nephritis
Emily Smitherman¹, Rouba Chahine¹, Aimee Hersh² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Disparities in long-term kidney outcomes have been documented in patients with childhood-onset systemic lupus erythematosus (cSLE) complicated by lupus nephritis (LN). However, there remains…
Abstract Number: 0760 • ACR Convergence 2022
Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors
Alexandra Ladouceur¹, Marina Amaral De Avila Machado², Marie Hudson¹, Cristiano Moura³ and Sasha Bernatsky³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of McGill University Health Center, Montréal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Since patients with pre-existing autoimmune conditions are commonly excluded from clinical trials with immune checkpoint inhibitors (ICI), we aimed to describe the characteristics of…
Abstract Number: 2080 • ACR Convergence 2022
Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
Rashmi Dhital¹, Monica Guma², Brian Pedersen¹, Ashbina Pokharel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³William Beaumont Hospital, Royal Oak, MI, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Patients with autoimmune rheumatic diseases presenting to the emergency department (ED) often have multi-organ pathology. SLE patients may be particularly prone to ED visits…
Abstract Number: 0070 • ACR Convergence 2022
Post-operative Delirium and Cognitive Impairment: An Analysis of Predictors and 120-day Outcomes in England Using the National Hip Fracture Database (NHFD)
Samuel Hawley¹, Dominic Inman², Celia Gregson¹, Michael Whitehouse¹, Antony Johansen³ and Andrew Judge¹, ¹University of Bristol, Bristol, United Kingdom, ²Northumbria Healthcare NHS Foundation Trust, Northumbria, United Kingdom, ³Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Post-operative delirium and cognitive impairment are common after hip fracture. We set out to identify risk factors and examine the association with returning home…
Abstract Number: 0826 • ACR Convergence 2022
Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Treatment in Patients with Adult Still’s Disease: An Analysis of a Japanese Claims Database
Yuko Kaneko¹, Hideto Kameda², Kei Ikeda³, Katsuhisa Yamashita⁴, Ryoto Ozaki⁵ and Yoshiya Tanaka⁶, ¹Keio University School of Medicine, Tokyo, Japan, ²Toho University, Tokyo, Japan, ³Chiba University Hospital, Chiba, Japan, ⁴Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, ⁵Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: Adult Still's disease (ASD), including adult-onset Still's disease and carry-over systemic juvenile idiopathic arthritis (sJIA), is treated with glucocorticoids (GC) with or without immunosuppressive…
Abstract Number: 2121 • ACR Convergence 2022
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Laura Pina Vegas¹, Emilie sbidian² and Pascal Claudepierre³, ¹Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ²Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³Paris Est Creteil University, Creteil, France
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed,…
Abstract Number: 0071 • ACR Convergence 2022
Workforce Changes and Characteristics of Adult Rheumatologists in a United States Medicare Claims Analysis
Melissa Mannion¹, Fenglong Xie¹, John FitzGerald², Amy Mudano³, Zihan Wan¹ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of California Los Angeles, Los Angeles, CA, ³Illumination Health, Hoover, AL, ⁴University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Prior studies have projected inadequate growth in the rheumatology provider workforce to keep up with population demand. The objective of this project was to…

« Previous Page
1
…
6
7
8
9
10
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].